Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Diazepam
Therapeutic Area : Neurology
Study Phase : Phase III
Recipient : Aquestive Therapeutics
Deal Size : $85.0 million
Deal Type : Agreement
Aquestive Therapeutics Receives First Milestone Payment from KYNMOBI™ Monetization
Details : The proceeds will help to execute on advancing company's key clinical and commercial initiatives, including the resubmission of its NDA for FDA approval of lead product Libervant™ Buccal Film and ongoing clinical trial for AQST-108.
Product Name : Libervant
Product Type : Controlled Substance
Upfront Cash : Undisclosed
November 23, 2020
Lead Product(s) : Diazepam
Therapeutic Area : Neurology
Highest Development Status : Phase III
Recipient : Aquestive Therapeutics
Deal Size : $85.0 million
Deal Type : Agreement
Lead Product(s) : MP-101
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 23, 2014
Lead Product(s) : MP-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MP-101
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2014
Lead Product(s) : MP-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
